Today,
1 in 21
people
is a cancer
survivor
In 1971,
1 in 69
people
was a cancer
survivor
2016
1971
new anticancer therapeutics.
new uses for previously
approved anticancer
therapeutics.
new diagnostic test.
new cancer
screening test.
new diagnostic imaging agents.
new medical device.
1
1
13
11
2
1
BETWEEN AUG. 1, 2015,
AND JULY 31, 2016,
THE FDA APPROVED:
RESEARCH EXPANDS
CANCER TREATMENT
OPTIONS
RESEARCH
CONTINUES
TO ADVANCE
IMMUNOTHERAPY
the first inhibitor to target
the most frequent cause of
resistance to EGFR inhibitors,
which is benefiting patients with
lung cancer like Ginger Tam, p. 72.
a first-in-class BCL2 inhibitor,
which is benefiting patients with
chronic lymphocytic leukemia
like Brian Parkinson, p. 76.
a new ALK inhibitor for treating
patients with lung cancer.
effectively treating patients
with bladder cancer like
Dave Maddison, p. 88.
allowing patients with
melanoma like Bob Ribbans
to live with no evidence
of disease, p. 94.
putting patients with multiple myeloma
like Steve Herz into remission, p. 92.
Leading to new and expanded uses for
molecularly targeted therapeutics, including:
Leading to four new immunotherapeutics
being approved by the FDA.
Three of these four treatments are:
